Skip to content

iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05049967
Acronym
iKnow
Enrollment
150
Registered
2021-09-20
Start date
2021-11-09
Completion date
2024-12-31
Last updated
2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Disease

Brief summary

Prospective observational study to further understand the value that a multi-omic approach has in individuals with a multi system, early onset disorder that does not have a molecular diagnosis by whole genome sequencing.

Detailed description

Understand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing

Interventions

None listed

Sponsors

Medical College of Wisconsin
CollaboratorOTHER
Illumina, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Undiagnosed probands must meet all of the following: 1. Must be able to understand and sign an informed consent and speak, read, and write in their native language (if the subject is a minor, their parent must have these abilities) 2. Proband between the ages of 12 months and 65 years 3. Study consent and participation of at least two unaffected family members (biological parents preferred. One biological parent and unaffected sibling allowed) 4. If applicable, unaffected sibling must be between the ages of 12 months and 65 years 5. A high prior probability of a multi-system early onset undiagnosed genetic disorder based on an expert medical assessment 6. Clinical WGS that did not yield a definitive diagnosis 7. It is preferred but not required that ancestry is from an under-represented population in current clinical genetic and translational research data repositories, especially African American, Asian American and Native American 8. Must be willing to have blood, urine and fecal samples taken to include participating family members Diagnosed probands must meet all of the following: 1. Must be able to understand and sign an informed consent and speak, read, and write in their native language (if the subject is a minor, its Parent or Legally Authorized Representative must have these abilities). 2. Proband between the ages of 12 months and 65 years 3. Study consent and participation of at least two unaffected family members (biological parents preferred. One biological parent and unaffected sibling allowed) 4. If applicable, unaffected sibling must be between the ages of 12 months and 65 years 5. Known genetic cause(s) of disease, disorder, or phenotypic defect through prior clinical whole genome sequencing 6. It is preferred but not required that ancestry is from an under-represented population in current clinical genetic and translational research data repositories, especially African American, Asian American and Native American 7. Must be willing to have blood, urine and fecal samples taken to include participating family members

Exclusion criteria

* Undiagnosed probands must not meet any: 1. Known non-genetic cause(s) of disease, disorder, or phenotypic defect 2. Principal Investigator decides that the study is not in the best interest of the proband Diagnosed probands must not meet any: 1\. Principal Investigator decides that the study is not in the best interest of the proband

Design outcomes

Primary

MeasureTime frameDescription
Based on analysis of data from completed clinical utility evaluation surveys following receipt of study results by the PI, assess whether a patient's change of management resulted from the multi-omic results120 DaysUnderstand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing

Secondary

MeasureTime frameDescription
Number of diagnoses yielded by each of the different orthogonally confirmed assay results120 DaysAssess the number of new diagnoses yielded by each approach
Analyze data from completed clinical utility evaluation surveys; number of patients with change of management and whether the change was due to a diagnosis yielded by multiomic results120 DaysAnalyze the clinical utility derived from a diagnosis
Data utilization of multi-omic dataset for scientific community120 DaysEstablish a multi-omic reference dataset from resource limited populations that can be used by the scientific community

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026